Medical imaging technology company Adaptix Limited (Adaptix) is delighted to announce the appointment of Willem Baralt, previously of Quanta Dialysis Technologies, as its new Chair.
Willem succeeds Steve McQuillan of Avingtrans, who was appointed in an interim capacity.
Willem took the Medtech company, Quanta Dialysis Technologies, through several rounds of financing, FDA clearance, commercialisation and the raising of $245m. Willem also took Flag Telecom through a NASDAQ IPO and has supported and led various mergers & acquisitions processes, both as an investment banker and executive.
Mark Evans, Adaptix’s CEO, stated, “We are pleased to announce that Willem Baralt has now joined the Company as Chair. Willem has previously served as Chief Executive Officer, Chief Financial Officer and Chair/NED and has significant international start-up, Private Equity-backed and listed company experience across Healthcare, Telecoms & Technology and Finance sectors. Willem has deep experience in facilitating commercial growth, fundraising, and building commercial teams and has served on Audit, Remunerations and Compensation committees. We welcome him to the Adaptix team and are delighted that he will be working with us to deliver the growth opportunity that our recent 510(k) clearance unlocks. We thank Steve McQuillan for his brief but effective tenure as Chair and are pleased that he remains on the Board to give the benefit of his experience as a listed-company CEO. ”
Willem Baralt, Adaptix’s chair, stated, “I am thrilled to be joining the Adaptix team, which is set to transform imaging diagnostics with its small, affordable, low dose, 3D system. With the receipt of regulatory clearance Adaptix has transitioned to a new series of challenges in order to commercialise this cutting-edge technology which is protected by 28 patent families and over 310 patents and I look forward to helping an extremely professional management team maximise the value of their innovations to society.
Steve McQuillan, the outgoing chair said: “The award of the 510(k) will be transformational for Adaptix and I step down leaving the Company with a strong management team, truly innovative products, and an exciting growth strategy. I am very optimistic about the future for Adaptix and am passing leadership of the Board to trusted hands in the form of Willem.”
About Adaptix Limited
Adaptix Limited is transforming radiology through the development of innovative 3D imaging technologies that are significantly better, safer, smaller, and more affordable than traditional radiology systems. At the core of their patent portfolio and commercialization strategy is a distributed Flat Panel X-ray Source (FPS) system which has applications across a multitude of global markets that are currently limited to 2D X-ray imaging systems where cost, speed to diagnostic result, location or dose concerns mean CT is not optimal. Adaptix’s central mission is to transform radiology by offering affordable low-dose 3D imaging at the point-of-care and allowing “3D-first” as the standard of care.
Carla Taylor – Group Marketing Manager
© 2023 by Adaptix Limited | Registered in England & Wales no. 06857417 | VAT No. 119317422